Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Rovalpituzumab Tesirine |
Synonyms | |
Therapy Description |
Rovalpituzumab Tesirine (Rova-T) is an antibody drug conjugate of pyrrolobenzodiazepine (PBD) cytotoxin D6.5 and human anti-delta-like 3 (DLL3) antibody, which targets and kills DLL-3 expressing tumor cells (PMID: 26311731). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rovalpituzumab Tesirine | Rova-T|SC16LD6.5 | Rovalpituzumab Tesirine (Rova-T) is an antibody drug conjugate of pyrrolobenzodiazepine (PBD) cytotoxin D6.5 and human anti-delta-like 3 (DLL3) antibody, which targets and kills DLL-3 expressing tumor cells (PMID: 26311731). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03061812 | Phase III | Rovalpituzumab Tesirine Topotecan | Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE) | Completed | USA | TUR | SWE | ROU | POL | NLD | LVA | ITA | HUN | HRV | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | 11 |
NCT02819999 | Phase I | Cisplatin + Etoposide + Rovalpituzumab Tesirine Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02874664 | Phase I | Rovalpituzumab Tesirine | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT02709889 | Phase Ib/II | Rovalpituzumab Tesirine | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Terminated | USA | 0 |
NCT02674568 | Phase II | Rovalpituzumab Tesirine | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) | Completed | 0 | |
NCT03543358 | Phase II | Rovalpituzumab Tesirine | A Long-Term Study of Rovalpituzumab Tesirine | Completed | USA | 0 |